McCloskey, E. V.
Borgstrom, F.
Cooper, C.
Harvey, N. C.
Javaid, M. K.
Lorentzon, M.
Kanis, J. A. http://orcid.org/0000-0002-3129-4326
Article History
Received: 9 February 2021
Accepted: 13 April 2021
First Online: 29 April 2021
Declarations
:
: JAK, NCH, ML and EVM are responsible for the creation and maintenance of FRAX but derive no financial benefit. EVM has received consultancy/lecture fees/grant funding/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, Sanofi Aventis, UCB, ViiV, Warner Chilcott and I3 Innovus. FB is employed by and is a shareholder of Quantify Research, a health economic research consultancy. CC reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. NCH has received consultancy/lecture fees/honoraria/grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Radius Health, Servier, Shire, UCB, Consilient Healthcare and Internis Pharma. MKJ declares no conflicts of interest. ML has received lecture fees from Amgen, Lilly, Meda, Renapharma and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health, all outside the presented work. JAK reports no additional competing interests.
Free to read: This content has been made available to all.